Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05882734 · ClinicalTrials.gov registry record · Phase 1
Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)
A Phase 1 study of Non-Small Cell Lung Cancer, sponsored by EMD Serono Research & Development Institute.
- Active
- Registry status
- Phase 1
- Development phase
- 61
- Enrollment target
- 20
- Study locations
NCT05882734: Active Phase 1 study of Non-Small Cell Lung Cancer, sponsored by EMD Serono Research & Development Institute.
NCT05882734 is a Phase 1 study of Non-Small Cell Lung Cancer that is active but no longer recruiting, run by EMD Serono Research & Development Institute. The registered enrollment target is 61 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05882734, a Phase 1 study of Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by EMD Serono Research & Development Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 61 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an Open-label, multicenter clinical study conducted in two Phases to establish the efficacy, safety, tolerability, and pharmacokinetics of the ataxia telangiectasia mutated and Rad3-related protein kinase (ATR) inhibitor Tuvusertib in Combination with Cemiplimab in Participants with Non-Squamous Non-Small Cell Lung Cancer (nsqNSCLC) that has Progressed on Prior Anti-PD-(L)1 and Platinum-based Therapies..
Conditions Studied
Interventions
- DRUG Cemiplimab
- DRUG M1774
Study Locations (20)
Other
- Institut Jules Bordet - Department of Institut Jules Bordet' - Anderlecht
- UZA - Oncology - Edegem
- Jessa Ziekenhuis Hospital - Hasselt
- Universitair Ziekenhuis Brussel - UZB - Jette
- UZ Leuven - Leuven
- CHU de Liège - PARENT - Liège
- CHU Angers - Hôpital Larrey - Service de Pneumologie - Angers
- Centre Hospitalier Intercommunal de Créteil - Service de Pneumologie - Créteil
- CHU Limoges - Hôpital Dupuytren - Unite d'Oncologie Thoracique et Cutanée - Limoges
- Hôpital de la Timone - CPCEM CIC - Bat F 1er étage - Marseille
- Hopital Arnaud de Villeneuve - Service de Pneumologie-Addictologie - Montpellier
- Groupe Hospitalier Sud - Hôpital Haut-Lévêque - Unité d'Explorations Fonctionnelles Respiratoires - Pessac
- ICO - Site René Gauducheau - Service d'Oncologie medicale - Saint-Herblain
- Universitaetsklinikum Giessen und Marburg GmbH - Medizinische Klinik und Poliklinik III - Giessen
Texas
- The University of Texas MD Anderson Cancer Center - Houston
- Millennium Research & Clinical Development - Houston
California
- UCLA Hematology and Oncology - Santa Monica - Santa Monica
Pennsylvania
- UPMC Cancer Center - Pittsburgh
Tennessee
- Tennessee Cancer Specialists - Biomedical Research - Knoxville
Virginia
- Virginia Cancer Specialists, PC - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2023-09-13 |
| Est. Completion | 2026-03-30 |
| Phase | Phase 1 |
What the registry record for NCT05882734 still lists
NCT05882734 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 61 participants, a relatively small participant target, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Cemiplimab is the first listed.
NCT05882734 names 20 study sites across 6 states, led by Other, Texas, California.
Frequently Asked Questions
What is clinical trial NCT05882734 about?
NCT05882734 is a clinical study titled "Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)". This is an Open-label, multicenter clinical study conducted in two Phases to establish the efficacy, safety, tolerability, and pharmacokinetics of the ataxia telangiectasia mutated and Rad3-related protein kinase (ATR) inhibitor Tuvusertib in Combination with Cemiplimab in Participants with Non-Squa...
What is the current status of trial NCT05882734?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 61 participants. The study started on 2023-09-13. Estimated completion is 2026-03-30.
What conditions does trial NCT05882734 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT05882734?
The interventions under investigation include: Cemiplimab (DRUG), M1774 (DRUG).
Who is sponsoring clinical trial NCT05882734?
This trial is sponsored by EMD Serono Research & Development Institute, which has 81 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05882734 being conducted?
This trial has 20 study locations across California, Pennsylvania, Tennessee, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05882734's enrollment target sits among peer trials
61 310th of 454 higher than 143 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04115306 · 61 participants · Phase 1
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
- NCT05070845 · 61 participants · Phase 2
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
- NCT05187832 · 61 participants · Phase 1
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
- NCT05269316 · 61 participants · Phase 1
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI